<DOC>
	<DOCNO>NCT00773786</DOCNO>
	<brief_summary>This double-blind crossover trial 20 patient stable COPD . Data study provide proof-of-concept information whether ( anticipate ) additional bronchodilator effect Brovana add tiotropium lead meaningful improvement patient-centered outcome , exercise capacity . This study evaluate effect short-term ( 1-week ) administration Brovana . If result positive , would provide preliminary data , multicenter investigation .</brief_summary>
	<brief_title>Effect Brovana Tiotropium Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Hypotheses test : Brovana nebulized twice daily add maintenance inhaled tiotropium therapy stable COPD patient increase : 1 . Forced expiratory volume 1 second ( FEV1 ) peak dose effect ( approximately 2 hour AM dose laboratory ) 2 . Resting exercise hyperinflation peak dose effect ( inspiratory capacity ( IC ) baseline iso-time exercise testing ; measurement approximately 2 ¼ hour AM dose tiotropium plus test drug . 3 . Exercise treadmill endurance time peak dose effect ( approximately 2 ¼ hour AM dose laboratory ) Patients : Twenty patient study Location : Section Pulmonary Critical Care , St. Francis Hospital &amp; Medical Center , Hartford , CT Excluded drug : 1 . Anticholinergic bronchodilator once-daily ( AM ) tiotropium standard dose 2 . Long act beta agonist bronchodilator 3 . Short act beta agonist bronchodilator must withhold within six hour laboratory test Allowed drug : 1 . Inhaled steroid 2 . Oral steroid 10 mg/day less , stable dose four week Removal patient study : 1 . Withdrawal consent 2 . Documented oxygen desaturation &lt; 85 % clinically significant problem ( angina , significant electrocardiogram ( ECG ) change , etc ) exercise test 3 . A significant adverse event 4 . Protocol violation include lack adherence COPD exacerbation study : If patient experience COPD exacerbation study require change medication addition medication ( oral steroid antibiotic ) study hold stability reach . At time , study resume , begin new , 1-week treatment /testing correspond study sequence exacerbation begin . If patient resume stability within four week second exacerbation , study terminate . Study design : This double-blind , crossover , single-site study COPD patient stable condition . All patient study randomized test drug Visit 2 steady-state tiotropium therapy , commercial long-acting beta-agonists ( LABA ) , use prn short-acting beta-agonists ( SABA ) . Only acute ( i.e. , 1-week ) effect Brovana study . SABA withhold midnight test day . Exercise test inspiratory capacity ( IC ) measurement Incremental steady-state endurance test perform treadmill Section Pulmonary Critical Care Medicine . The incremental test ( Visit 1 ) perform symptom-limited maximum , goal test duration approximately 10 minute . The protocol use Porszasz et al use simultaneous increase treadmill speed incline , setting base estimate maximal workrate . Warm-up 1 mph 1 % grade . This follow 30-second interval increase speed incline . Patients breath breath measurement expire air use Sensormedics equipment , via mouthpiece . IC measurement also measure rest every minute exercise . Endurance test ( Visit 2 , 4 , 5 ) 75 % maximal rate determine initial test . For exercise capacity , duration exercise time primary outcome variable . IC measure rest every minute exercise . An ECG perform exercise test , continuous pulse oximetry monitor . A physician attendance test . Primary Efficacy Variables : 1 . Change FEV1 near peak effect ( ~ 2 hour AM laboratory dose tiotropium plus test drug ) : 1 . The primary comparison Δ FEV1 ( @ 2-hours Tiotropium + Brovana minus pre-dose FEV1 ) versus Δ FEV1 ( @ 2-hours Tiotropium + Placebo minus pre-dose FEV1 ) 2 . The analysis perform use repeated-measures design , PROC GLM Repeated , SAS : 2 . Change treadmill endurance time ~75 % maximum ( Δ endurance time ) Brovana versus placebo : baseline test tiotropium alone compare test tiotropium + study drug . 1 . The primary comparison Δ endurance time ( @ 2 ¼ hour Tiotropium + Brovana compare tiotropium alone 2 . The analysis perform use repeated-measures design , PROC GLM Repeated , SAS 3 . Change static ( rest ) , iso-time , peak exercise IC measurement , use estimate hyperinflation ; Brovana versus placebo : baseline test tiotropium alone compare test tiotropium + study drug . . The primary co-comparisons : i. Δ IC rest ( static hyperinflation ) ( @ 2 ¼ hour Tiotropium + Brovana compare tiotropium alone ii . Δ IC iso-time ( static hyperinflation ) ( @ 2 ¼ hour Tiotropium + Brovana compare tiotropium alone . We sure iso-time use , patient go six minute exercise , use six minute mark . b . The analysis perform use repeated-measures design , PROC GLM Repeated , SAS Sample Size Estimation The van Noord sit earlier power study assume ~ 140 mL standard deviation pair difference FEV1 ( determine earlier trial ) , difference ~ 50 mL , power 0.90 . They achieve 150 mL ( 0.150 L ) difference FEV1 . For study , use difference 150 mL , standard deviation 140 mL , power 0.80 , 16 patient would sufficient . In study O'Donnell et al combination fluticasone 250 mcg / salmeterol 50 mcg compare salmeterol alone placebo . Outcome variable include spirometry , lung volume exercise endurance time 75 % maximal cycle ergometer . The average improvement ( compare placebo ) FEV1 Day 1 ( take graph ) 200 mL combination salmeterol . The treatment-difference improvement exercise endurance time combination 131 ± 31 second ( p. &lt; 0.004 ) , represent 22 % improvement . For salmeterol alone 49 ± 37 second . Our study would use treadmill rather cycle ergometer ; probably lead dyspnea-limitation leg fatigue limitation . We predict Δ FEV1 two hour post dose ( compare tiotropium alone ) Brovana + tiotropium study ~ 150 mL - Δ dissimilar O'Donnell study Δ . To detect 90 second difference endurance time ( 1/2 way 131 second 49 second ) , assume standard deviation ( SD ) 35 second , study would amply power . Study Sequence Visit 1 : 1 . Informed consent obtain 2 . Inclusion/exclusion criterion meet 3 . History physical examination perform 4 . Post-bronchodilator spirometry inclusion criterion 5 . Patient start tiotropium , necessary ; tiotropium dispense , necessary 6 . If necessary : long act bronchodilator ( LABA ) discontinue , ipratropium discontinue 7 . Levalbuterol MDI dispense prn use 8 . Appointment give Visit 1 Visit 2 : 1 day ( patient already tiotropium ) 1 week ( start tiotropium ) Visit 1 : 1 . Brief history limit physical 2 . Spirometry maintenance tiotropium , AM dose SABA withhold ~ 6 hour 3 . Incremental treadmill endurance test 4 . Patient instruct continue take tiotropium daily morning ( qAM ) levalbuterol MDI prn 5 . Appointment 2-week follow-up Visit 3 : 1 week Visit 2 , maintenance tiotropium 1 . Brief history limit physical 2 . Pre-bronchodilator spirometry ( maintenance tiotropium , levalbuterol withheld ) 3 . Tiotropium give ( open label ) 4 . Spirometry 2 hour tiotropium dose 5 . ECG 2 ¼ hour tiotropium dose 6 . Endurance treadmill endurance test ( include IC measurement ) 2 ¼ hour open-label tiotropium dose 7 . Nebulizer dispense 8 . Blinded Test drug # 1 dispense ( Brovana placebo , 20 unit dos ) , instruction take via nebulizer bid , tiotropium continue qAM , levalbuterol MDI continue prn 9 . Appointment 1 week follow-up Visit 4 : 1 week Visit 3 , test drug # 1 1 . Brief history limit physical 2 . Pre-dosing spirometry ( maintenance tiotropium Test Drug # 1 , levalbuterol withheld ) 3 . Tiotropium Test Drug # 1 give 4 . Spirometry 2 hour dose 5 . ECG 2 ¼ hour dose 6 . Endurance treadmill endurance test 2 ¼ hour dose 7 . Begin wash-out period : Tiotropium open-label plus prn levalbuterol continue ; placebo give via nebulizer , take bid ( part single-blinded ) 8 . Appointment 1 week follow-up Visit 5 : 1 week Visit 4 , washout 1 . Brief history limit physical 2 . Spirometry AM 3 . Blinded Test drug # 2 dispense ( Brovana placebo , 20 unit dos ) , instruction take via nebulizer bid , tiotropium continue qAM , levalbuterol MDI continue prn 4 . Appointment 1 week follow-up Visit 6 : 1 week Visit 5 , test drug # 2 1 . Brief history limit physical 2 . Pre-dosing spirometry ( maintenance tiotropium Test Drug # 2 , levalbuterol withheld ) 3 . Tiotropium Test Drug # 2 give 4 . Spirometry 2 hour dose 5 . ECG 2 ¼ hour dose 6 . Endurance treadmill endurance test IC measurements 2 ¼ hour dose 7 . Study terminate</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Informed consent ( Approval St. Francis Hospital Institutional Review Board ( IRB ) require study initiation ) 2 . Adults , age &gt; 40 year 3 . A clinical diagnosis COPD , spirometric confirmation : postbronchodilator force expiratory volume 1 second / force vital capacity ( FEV1/FVC ) ( &lt; 0.70 4 . Moderate , severe severe airflow limitation GOLD criterion . 5 . Clinically stable respiratory disease 6 . The perceived ability participate pulmonary testing exercise test 7 . COPD , stable state Exclusion criterion : 1 . Women childbearing potential 2 . Asthma 3 . Supplemental oxygen use anticipate oxygen desaturation &lt; 85 % peak exercise ( patient desaturate 85 % incremental study exclude ) 4 . Comorbidity would interfere patient participate study , include exercise testing . Examples include unstable cardiac disease , arthritis , psychological problem would interfere participation 5 . An exacerbation require therapy change maintenance COPD therapy within six week test 6 . A history prolong QT interval 7 . Recent exacerbation COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>Bronchodilator</keyword>
	<keyword>arformoterol</keyword>
	<keyword>tiotropium</keyword>
</DOC>